Cargando…
Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
Background: Human epidermal growth factor receptor 2 (ERBB2, HER-2) exon 20 insertion (ERBB2ex20ins) remains a refractory oncogenic driver in lung cancer. So far there is limited data showing the co-occurring mutation background of ERBB2ex20ins in Chinese lung cancer and its relationship with respon...
Autores principales: | Yuan, Bo, Zhao, Jun, Zhou, Chengzhi, Wang, Xiumei, Zhu, Bo, Zhuo, Minglei, Dong, Xilin, Feng, Jiemei, Yi, Cuihua, Yang, Yunpeng, Zhang, Hua, Zhou, Wangyan, Chen, Zhengtang, Yang, Sheng, Ai, Xinghao, Chen, Kehe, Cui, Xuefan, Liu, Difa, Shi, Chunmei, Wu, Wei, Zhang, Yanjun, Chang, Lianpeng, Li, Jin, Chen, Rongrong, Yang, Shuanying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236802/ https://www.ncbi.nlm.nih.gov/pubmed/32477948 http://dx.doi.org/10.3389/fonc.2020.00729 |
Ejemplares similares
-
Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
por: Liu, Zhefeng, et al.
Publicado: (2018) -
Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma
por: Jian, Hong, et al.
Publicado: (2019) -
Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma
por: Mao, Xinfang, et al.
Publicado: (2016) -
Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
por: Köhler, Jens
Publicado: (2017) -
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
por: Modjtahedi, Helmout, et al.
Publicado: (2014)